Mymetics Corp. (OTC: MYMX) is a Switzerland-based biotechnology company focused on the development of next-generation preventative vaccines for infectious diseases. The company’s vaccines are designed to induce protection against early transmission and infection. They focus on the mucosal immune response … Continue reading →

RXi Pharmaceuticals Corp. (NASDAQ: RXII) is a biotechnology company focused on discovering and developing innovative therapeutics, primarily in the areas of dermatology and ophthalmology, addressing high-unmet medical needs. The company’s discovery and clinical development programs are based on siRNA technology … Continue reading →

Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC) is a biopharmaceutical company developing oral therapies that target the various phases of cell cycle control for the treatment of cancer and other serious diseases. Professor Sir David Lane, a recognized leader in the field … Continue reading →

Actinium Pharmaceuticals, Inc. (NYSE: ANTM) is a biopharmaceutical company focused on the development of cancer drugs. The company’s product candidates are based on its patented technology, which combines the cancer targeting precision of monoclonal antibodies with the power of alpha … Continue reading →

RepliCel Life Sciences Inc. (OTC: REPCF) is a regenerative medicine company focused on developing autologous cell therapies that address conditions caused by a deficit of healthy cells required for normal healing and function. The company’s product pipeline is comprised of … Continue reading →

SciClone Pharmaceuticals (NASDAQ: SCLN) is a specialty pharmaceutical company with a substantial commercial business in China and a product portfolio spanning major therapeutic markets including oncology, infectious diseases and cardiovascular disorders. The company’s proprietary lead product, ZADAXIN® (thymalfasin), is approved in over … Continue reading →

Sorrento Therapeutics, Inc. (NASDAQ: SRNE) is a clinical-stage biopharmaceutical company developing new treatments for cancer, as well as associated pain, inflammation and immune diseases. The company recently licensed multiple late-stage biosimilar and biobetter antibodies for oncology and inflammation diseases in … Continue reading →

Cytosorbents Corp. (NASDAQ: CTSO) is a critical care-focused immunotherapy company using blood purification to control severe inflammation with the goal of preventing or treating multiple organ failure in life-threatening illnesses. CytoSorb®, the company’s flagship product, is approved in the EU … Continue reading →